Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Blood (2019) 133 (26): 2765–2775.

https://doi.org/10.1182/blood-2019-01-896290

Published: 2019

Includes: Supplemental data

Journal Articles

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Anne Calleja, Sandra De Barros, Camille Vinson, PharmD, Caroline Protin, MD, Lucie Oberic, MD, Fanny Gallais, Melanie White-koning, Etienne Chatelut, Christian Recher, MD PhD, Sarah Cadot, PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Fabien Despas, PharmD, PhD

Blood (2018) 132 (Supplement 1): 3960.

https://doi.org/10.1182/blood-2018-99-116532

Published: 2018

Journal Articles

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Leylah M. Drusbosky, PhD, Aneel Paulus, MD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD, Ansu Kumar, MS, Neeraj Kumar Singh, B.Tech, Yashaswini Ullal, BE, Priyanka Bhargav, BE, Humera Azam, MS, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Asher A. Chanan-Khan, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 4278.

https://doi.org/10.1182/blood.V130.Suppl_1.4278.4278

Published: 2017

Journal Articles

Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach

Loic Ysebaert, MD PhD, Sarah Cadot, PhD, Salim Kanoun, MD, Soleakhena Ken, Christian Recher, MD PhD, François Malgouyres, Sebastien Gadat, Loic Dupre, PhD, Anne Quillet Mary, PhD

Blood (2017) 130 (Supplement 1): 2990.

https://doi.org/10.1182/blood.V130.Suppl_1.2990.2990

Published: 2017

Journal Articles

Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients

Martin Gauthier, Florence Durrieu, Michael Peres, MD, Elodie Martin, MSc, Thomas Filleron, PhD, Christian Recher, MD PhD, Anne Quillet Mary, PhD, Loic Ysebaert, MD PhD

Blood (2017) 130 (Supplement 1): 1731.

https://doi.org/10.1182/blood.V130.Suppl_1.1731.1731

Published: 2017

Journal Articles

CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo

Loïc Ysebaert, MD PhD, Christian Klein, PhD, Anne Quillet-Mary, PhD

Blood (2015) 126 (23): 4157.

https://doi.org/10.1182/blood.V126.23.4157.4157

Published: 2015

Journal Articles

Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?

Loic Ysebaert, MDPhD, Christian Klein, PhD, Anne Quillet-Mary, PhD

Blood (2014) 124 (21): 1980.

https://doi.org/10.1182/blood.V124.21.1980.1980

Published: 2014

Journal Articles

“Don't Eat me”: CD47 and LFA-1 Modulate CLL Response to Nurselike Cells-Mediated Antibody-Dependent Phagocytosis Induced by Rituximab and Obinutuzumab (GA101)

Loic Ysebaert, MD PhD, Emilie Laprevotte, Christian Klein, PhD, Guy Laurent, MD PHD, Anne Quillet-Mary, Mary Poupot, Jean-Jacques Fournié, PhD

Blood (2011) 118 (21): 1762.

https://doi.org/10.1182/blood.V118.21.1762.1762

Published: 2011

Journal Articles

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study

Camille Laurent, Sabina Müller, Catherine Do, Talal Al-Saati, Sophie Allart, Luigi Maria Larocca, Stefan Hohaus, Sophie Duchez, Anne Quillet-Mary, Guy Laurent, Pierre Brousset, Salvatore Valitutti

Blood (2011) 118 (20): 5371–5379.

https://doi.org/10.1182/blood-2011-04-345777

Published: 2011

Includes: Supplemental data

Journal Articles

Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells

Loic Ysebaert, Emilie Laprévotte, Christian Klein, PhD, Guy Laurent, MD, Jean-Jacques Fournié, PhD, Anne Quillet-Mary

Blood (2010) 116 (21): 2459.

https://doi.org/10.1182/blood.V116.21.2459.2459

Published: 2010

Journal Articles

Rituximab inhibits B-cell receptor signaling

Samar Kheirallah, Pierre Caron, Emilie Gross, Anne Quillet-Mary, Justine Bertrand-Michel, Jean-Jacques Fournié, Guy Laurent, Christine Bezombes

Blood (2010) 115 (5): 985–994.

https://doi.org/10.1182/blood-2009-08-237537

Published: 2010

Journal Articles

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

Julie Gertner-Dardenne, Cecile Bonnafous, Christine Bezombes, Aude-Hélène Capietto, Virginie Scaglione, Sophie Ingoure, Delphine Cendron, Emilie Gross, Jean-François Lepage, Anne Quillet-Mary, Loîc Ysebaert, Guy Laurent, Hélène Sicard, Jean-Jacques Fournié

Blood (2009) 113 (20): 4875–4884.

https://doi.org/10.1182/blood-2008-08-172296

Published: 2009

Includes: Supplemental data

Journal Articles

TNFα Stimulates NKG2D-Mediated Lytic Activity of Acute Myeloid Leukemic Cells.

Guy Laurent, Fabien Guilloton, Aurelie de Thonel, Christine Jean, Cecile Demur, Veronique De Mas, Anne Quillet-Mary

Blood (2005) 106 (11): 4411.

https://doi.org/10.1182/blood.V106.11.4411.4411

Published: 2005

Journal Articles

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

Christine Bezombes, Solène Grazide, Céline Garret, Claire Fabre, Anne Quillet-Mary, Sabina Müller, Jean-Pierre Jaffrézou, Guy Laurent

Blood (2004) 104 (4): 1166–1173.

https://doi.org/10.1182/blood-2004-01-0277

Published: 2004

Journal Articles

Protein kinase Cζ mediated Raf-1/extracellular-regulated kinase activation by daunorubicin

Véronique Mansat-De Mas, Hélène Hernandez, Isabelle Plo, Christine Bezombes, Nicolas Maestre, Anne Quillet-Mary, Rodolphe Filomenko, Cécile Demur, Jean-Pierre Jaffrézou, Guy Laurent

Blood (2003) 101 (4): 1543–1550.

https://doi.org/10.1182/blood-2002-05-1585

Published: 2003

Journal Articles

Role of protein kinase C ζ isoform in Fas resistance of immature myeloid KG1a leukemic cells

Aurélie de Thonel, Ali Bettaı̈eb, Christine Jean, Guy Laurent, Anne Quillet-Mary

Blood (2001) 98 (13): 3770–3777.

https://doi.org/10.1182/blood.V98.13.3770

Published: 2001

Journal Articles

Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin

Alain Pierre Bruno, Dominique Lautier, Aurélie de Thonel d'Orgeix, Guy Laurent, Anne Quillet-Mary

Blood (2000) 96 (5): 1914–1920.

https://doi.org/10.1182/blood.V96.5.1914

Published: 2000

NARROW

Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

Interest of Dosing of Ibrutinib in B-Cell Lymphoid Malignancies: Data from a Real-Life, Phase 4 Study

Predicting Mechanisms of Ibrutinib-Resistance in Chronic Lymphocytic Leukemia (CLL) Using Computational-Based Modeling for Personalized Therapy with Clinical Validation

Computational Integration to Model Tumor Dynamics in CLL Patients Treated with the Btk Inhibitor Ibrutinib (CompuTreatCLL): First Results of an Integrative Systems Biology Approach

Immune Recovery Refines the Prognostic Impact of Minimal Residual Disease on Overall and Progression Free Survivals after Frontline Fludarabine, Cyclophosphamide and Rituximab (FCR) in CLL Patients

CLL Cells from Ibrutinib-Induced Lymphocytosis of Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Are Responsive to Obinutuzumab, but Not Rituximab, Ex Vivo

Ibrutinib Exposure and B-Cell Depletion Induced By Anti-CD20 Monoclonal Antibodies Rituximab and Obinutuzumab: Is There a Rationale for Combination Studies?

“Don't Eat me”: CD47 and LFA-1 Modulate CLL Response to Nurselike Cells-Mediated Antibody-Dependent Phagocytosis Induced by Rituximab and Obinutuzumab (GA101)

Distribution, function, and prognostic value of cytotoxic T lymphocytes in follicular lymphoma: a 3-D tissue-imaging study

Clinical and Biological Characteristics Associated with In Vitro Activity of Anti-CD20 Monoclonal Antibodies, Rituximab and GA101, Against Chronic Lymphocytic Leukemia Cells

Rituximab inhibits B-cell receptor signaling

Bromohydrin pyrophosphate enhances antibody-dependent cell-mediated cytotoxicity induced by therapeutic antibodies

TNFα Stimulates NKG2D-Mediated Lytic Activity of Acute Myeloid Leukemic Cells.

Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains

Protein kinase Cζ mediated Raf-1/extracellular-regulated kinase activation by daunorubicin

Role of protein kinase C ζ isoform in Fas resistance of immature myeloid KG1a leukemic cells

Acute myeloblastic leukemic cells acquire cellular cytotoxicity under genotoxic stress: implication of granzyme B and perforin

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only